Spotlight Pathology focuses on creating decision support tools that leverage artificial intelligence to enhance the diagnosis of blood cancers. The company's medical diagnostic platform integrates bioinformatics and genomics, utilizing AI to analyze digital histopathology and multiplex immunofluorescence images. This innovative approach aids healthcare professionals in detecting and diagnosing blood cancers at an early stage, ultimately improving patient outcomes. By combining advanced technology with medical expertise, Spotlight Pathology aims to transform the diagnostic landscape for blood-related malignancies.
HeadBox is an online marketplace that connects corporate and SME bookers with owners of creative and inspiring event spaces across the UK. The platform simplifies the event planning process by allowing users to search for, book, and pay for venues online, catering to a variety of events such as workshops, meetings, product launches, and corporate parties. By providing a seamless experience, HeadBox helps clients save time and effort in organizing their events, making it easier to find suitable spaces for their needs.
AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.
Thalia Design Automation Ltd. operates as a semiconductor electronic design automation (EDA) company that provides software solutions to assist in the design of analog and mixed signal integrated circuits.
Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve and the nerve fibres from the retina. Once damage is detected, it is usually permanent and therefore it is vital to make the diagnosis as soon as possible to commence treatment. The ROS product is based on patented technology covering the use of visual field testing using a cursor and LED screen: the product is currently configured for use within a Windows environment and has two developed tests in play; the Full Threshold Test and the Suprathreshold Test. The ROS application will be hosted remotely and deployed via the latest in Cloud technology enabling users to access the application from wherever they are situated. All data is stored on secure encrypted servers to ensure data privacy and security is maintained at all times.
GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.
Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.
Touch Biometrix Ltd is a UK-based company that designs and develops innovative fingerprint authentication sensors for the consumer electronics sector. Established in 2017 and headquartered in Conwy, the company focuses on creating a versatile sensing and algorithm platform that allows for fingerprint sensors of various shapes and sizes. This technology is engineered for seamless integration into mobile devices and other smart objects, enhancing user-friendly identity authentication. By employing advanced sensor designs and algorithms, Touch Biometrix aims to provide a secure and convenient alternative to traditional password systems, enabling a range of products to deliver high-performance fingerprint authentication at competitive cost points.
FluoretiQ is a medical device company designing simple and effective bacterial detection systems for rapid diagnosis of infection. They developing a new solution that combines proprietary nanomaterials and optical sensing technologies to enable the identification of harmful bacteria in minutes. The company nanotechnology utilizes receptor-mediated sensing and Quantum-enhanced optics for the rapid identification of bacterial infection. FluoretiQ developed NANOPLEXa rapid diagnostic platform that identifies and enumerates bacterial pathogens in less than 15 minutes. The NANOPLEXa ensures that patients receive the most effective antibiotic treatment from the start. Their products easy-to-use, providing clinicians with the data to support accurate-same-day diagnosis and more appropriate antibiotic selection. FlouretiQ was founded in 2017 and is headquartered in Bristol, United Kingdom.
Pathfinder Medical is focused on creating a novel electronic guidance system that facilitates minimally invasive connections between blood vessels. This innovative catheter-based technology is designed specifically for treating kidney failure, allowing for vascular access creation that can be performed outside of traditional operating rooms. The system aims to improve the reliability of hemodialysis access for patients, addressing a significant market opportunity valued at £1.6 billion annually. By reducing the likelihood of failure, Pathfinder Medical’s solution enhances treatment options for patients requiring dialysis, showcasing its potential impact in the healthcare sector.
Aegiq Ltd. is a company based in Sheffield, United Kingdom, specializing in semiconductor-based quantum photonic chips. Established in 2019, it focuses on developing a universal quantum computing platform that integrates photonic quantum computing and networking technologies. Aegiq's solutions cater to a variety of industries, including defense, aerospace, cybersecurity, and artificial intelligence, addressing complex computational challenges with an emphasis on speed, compactness, and modularity. The company's innovative hybrid integrated photonics approach aims to facilitate large-scale quantum computing with the capacity for multi-million qubit operations, ultimately contributing to advancements in quantum cybersecurity and networking.
Glucose Republic is a developer of software focused on enhancing metabolic health through personalized nutrition solutions. The company offers a specialized application that enables users to measure and predict their metabolic responses based on their dietary intake and physical activity. By leveraging biology-influenced technology, Glucose Republic aims to provide individuals with tools to better understand their metabolism, ultimately helping them to eat and live healthier.
Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, specializing in the development of portable infrared spectroscopy devices for the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Established in 2013, the company has created a hand-held device that utilizes Fourier transform infrared spectroscopy (FTIR) to analyze sputum samples for specific biomarkers associated with COPD. This innovative technology allows patients to perform diagnoses and monitor their health from home, facilitating early detection and management of respiratory diseases. By identifying particular spectral signatures in the samples, the device supports healthcare professionals in assessing and understanding patients' conditions more effectively.
SmallSpark is a Welsh aerospace company based in Cardiff Bay, focused on developing hybrid engine launch vehicle technology. The company aims to significantly reduce the cost of access to space, making it feasible for a wide range of clients to send payloads into orbit or on sounding rockets. By offering low-cost space vehicles, SmallSpark enables customers to utilize advanced hybrid rocket motor technology, thereby democratizing access to space and fostering broader commercial opportunities in the aerospace sector.
HeadBox is an online marketplace that connects corporate and SME bookers with owners of creative and inspiring event spaces across the UK. The platform simplifies the event planning process by allowing users to search for, book, and pay for venues online, catering to a variety of events such as workshops, meetings, product launches, and corporate parties. By providing a seamless experience, HeadBox helps clients save time and effort in organizing their events, making it easier to find suitable spaces for their needs.
Ferryx is focused on addressing the challenges posed by gut inflammation, particularly conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), which collectively affect millions globally. The company specializes in the development of live biotherapeutics, creating safe and effective bacterial products aimed at preventing and treating gastrointestinal inflammation. By providing natural alternatives to conventional medications, Ferryx seeks to offer solutions that minimize negative side effects and enhance the well-being of both humans and animals suffering from these debilitating conditions.
GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.
Viscgo Limited is a company based in Warrington, United Kingdom, founded in 2015. It specializes in designing, developing, and delivering innovative devices and technology aimed at improving the management of dysphagia, a condition that affects individuals with swallowing disorders. Viscgo's product line includes drink thickness testers that enable accurate measurement of the viscosity of various liquids and textured-modified foods. This technology aids patients, caregivers, and clinicians by ensuring that fluids are properly mixed to provide a smooth consistency, thereby enhancing the safety and quality of care in settings such as hospitals, care homes, schools, and nurseries.
Filisia addresses the training, rehabilitation and access requirements of people with special education and rehabilitation needs through creative and connected technology. Filisia estimates that there are over 150 million people globally with special education and rehabilitation needs. Cognitive, communication, and physical training is essential, but expensive, repetitive, and often viewed as not always engaging for the person receiving it. Existing technological solutions are often viewed as unattractive and do not provide significant data insights. The result is slower recovery and training, suboptimal therapy results and increased care costs. Filisia’s patent pending software has a number of key features that have been designed with therapists. The software has modules for differing conditions and offers gamified rehabilitation exercises. Multiple difficulty levels tests both physical and cognitive abilities. The software also collects and displays data on clients’ and can record cumulative data to show improvement, flat line or decline in the users outputs.
VoxSmart Limited is a telecommunications software provider focused on the financial services sector, offering solutions to manage business risk and comply with regulatory requirements. Founded in 2006 and based in London, the company specializes in its VSMART platform, which captures, records, stores, transcribes, and analyzes mobile communications, including calls, messages, and voicemails, across various devices and networks. By turning communications data into actionable insights, VoxSmart enables firms to enhance their understanding of employee conduct, operational efficiency, and potential business opportunities. The company has formed a strategic alliance with Eventus Systems, Inc., further extending its capabilities in the market.
We help Startups with their digital products.
Carocell Bio is a biotechnology company focused on developing innovative medicines to address serious inflammatory disorders. The company aims to provide safer and more effective treatment options for conditions such as atopic dermatitis, inflammatory bowel disease, and burn-related injuries. Its platform utilizes human biopsy samples to enhance the management of these inflammatory conditions, allowing medical professionals to prevent scarring following surgeries or burns. With a goal of becoming revenue-generating within five years, Carocell Bio plans to drive its lead project towards a potential exit through out-licensing or trade sale, thereby advancing its commitment to improving patient outcomes in inflammatory disorders.
Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.
NanOptima is focused on improving the treatment of retinal diseases through innovative ophthalmic drug delivery technology. The company is developing controlled-release drug depots that aim to reduce the frequency of intraocular injections to twice a year, enhancing patient compliance and comfort. By maintaining consistent intraocular medication concentrations, NanOptima addresses the limitations of traditional injection methods. Their approach involves utilizing approved drugs to provide effective treatment for conditions such as wet age-related macular degeneration. Additionally, the technology is designed to facilitate the early detection of eye diseases and disorders, ultimately aiming to improve patient outcomes and reduce the risk of incomplete treatment.
LogChain is a digital platform focused on transforming supply chain management to enhance efficiency, security, and compliance. By utilizing distributed ledger technology, LogChain captures data and documentation at every stage of the trade process, particularly benefiting chemical manufacturers and shippers. This approach allows clients to deliver shipments with reduced costs, time, and risk. The platform streamlines workflows, including customs clearance and logistics management, making it suitable for businesses of all sizes, from micro-businesses to multinationals. LogChain's commitment to transparency and security, along with its seamless integration into existing systems, positions it as a valuable partner in optimizing supply chains and improving overall operational performance.
SmallSpark is a Welsh aerospace company based in Cardiff Bay, focused on developing hybrid engine launch vehicle technology. The company aims to significantly reduce the cost of access to space, making it feasible for a wide range of clients to send payloads into orbit or on sounding rockets. By offering low-cost space vehicles, SmallSpark enables customers to utilize advanced hybrid rocket motor technology, thereby democratizing access to space and fostering broader commercial opportunities in the aerospace sector.
Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.
Liverpool ChiroChem (LCC) is a chemistry-focused contract research organization (CRO) specializing in the production of chiral small molecules for the biotechnology and pharmaceutical sectors. The company offers a range of products, including building blocks, fragments, and screening compounds that facilitate small molecule drug discovery. LCC's advanced chemical technologies enable efficient access to novel chiral building blocks, which are essential for hit identification and hit-to-lead optimization. Their catalytic methods produce a diverse array of chiral amines with high enantiomeric purity. With an initial emphasis on chiral piperidines and sp3-rich nitrogen heterocycles, LCC's offerings are particularly valuable for drug development due to their favorable pharmacokinetic properties, such as improved solubility and bioavailability. The company's innovative technologies have emerged from years of research in asymmetric hydrogenation and Pd-coupling, and LCC actively collaborates with clients to enhance key steps in synthetic processes.
Blossom Genetics produces proprietary medicinal cannabis genetics and products. Our mission is to advance medicinal cannabis through scientific research to develop best in class products for our customers.
Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.
Ostara Biomedical Ltd. is a biotechnology company focused on enhancing artificial reproduction technologies for various mammalian species. Based in Liverpool, United Kingdom, the company has developed a novel vaginal pessary system designed to induce pseudopregnancy in female mice, facilitating embryo transfers. Ostara's ProgenySys™ product suite aims to improve the success rates of artificial reproduction in both domestic livestock and laboratory rodents, while also addressing ethical concerns by minimizing the number of animals required in breeding programs. Founded in 2012, Ostara serves customers both in the UK and internationally, contributing to advancements in reproductive technologies that support individuals and healthcare providers on the fertility journey.
Thalia Design Automation Ltd. operates as a semiconductor electronic design automation (EDA) company that provides software solutions to assist in the design of analog and mixed signal integrated circuits.
Pacla Medical is the creator of BackHug, an innovative robotic device designed to alleviate back pain and improve spinal flexibility. Utilizing patent-protected technology, BackHug employs 26 robotic fingers to deliver deep tissue pressure to the center of the back and shoulder blades, achieving an average pain reduction of 51%. The accompanying BackHug App personalizes treatment plans through an in-app consultation, allowing users to adjust strength and parameters in real-time. The device also monitors back relaxation levels and utilizes artificial intelligence to optimize treatment based on user data. With a growing customer base, users report significant savings on traditional treatments, averaging over $500 per month, and typically engage with the device 2-3 times a week. Employing approximately 16 staff across the UK and Vietnam, Pacla Medical aims to transform the lives of over 197 million individuals suffering from back pain and related conditions.
Filisia addresses the training, rehabilitation and access requirements of people with special education and rehabilitation needs through creative and connected technology. Filisia estimates that there are over 150 million people globally with special education and rehabilitation needs. Cognitive, communication, and physical training is essential, but expensive, repetitive, and often viewed as not always engaging for the person receiving it. Existing technological solutions are often viewed as unattractive and do not provide significant data insights. The result is slower recovery and training, suboptimal therapy results and increased care costs. Filisia’s patent pending software has a number of key features that have been designed with therapists. The software has modules for differing conditions and offers gamified rehabilitation exercises. Multiple difficulty levels tests both physical and cognitive abilities. The software also collects and displays data on clients’ and can record cumulative data to show improvement, flat line or decline in the users outputs.
Touch Biometrix Ltd is a UK-based company that designs and develops innovative fingerprint authentication sensors for the consumer electronics sector. Established in 2017 and headquartered in Conwy, the company focuses on creating a versatile sensing and algorithm platform that allows for fingerprint sensors of various shapes and sizes. This technology is engineered for seamless integration into mobile devices and other smart objects, enhancing user-friendly identity authentication. By employing advanced sensor designs and algorithms, Touch Biometrix aims to provide a secure and convenient alternative to traditional password systems, enabling a range of products to deliver high-performance fingerprint authentication at competitive cost points.
As featured on the BBC, TimeOut London, Evening Standard, and Conde Nast Traveler. TubeChat is the only free to download iPhone group messaging app that works on the London Underground where there is no cellular or wifi. TubeChat uses Bluetooth on your iPhone to make automatic incognito connections to people with the same app up to 200 meters away allowing you to chat and play underground. What can you do on TubeChat? LINK - UP: Make new friends. TubeChat facilitates real-life conversations and meetings in areas where other popular social networking or dating apps just don’t work. CHAT: Group chat safely completely ad-free with up to 10 other users nearby. We don’t reveal your identity unless you want to. Maintain your mystery by not updating your profile picture. PLAY: With TubeChat you will be able to play classic games such as I Spy. Have you got a favourite game you’d like to see in the app? Let us know and we’ll see what we can do.
Compono is a software company focused on enhancing recruitment and talent management through intelligent solutions. Its platform utilizes advanced data analysis and algorithms to match candidates with specific job requirements effectively. By actively comparing and ranking candidates based on their skills and suitability, Compono assists recruiters in selecting the right employees for various roles. This approach not only optimizes talent acquisition but also aims to improve organizational design and employee engagement, ultimately unlocking the potential of the workforce. Through its innovative technology, Compono seeks to make careers more rewarding and productive for individuals while supporting businesses in their hiring processes.
Keia is the online destination that connects practitioners and consumers of wellness services, spanning 27 areas and growing, with a mission to make wellness services accessible and affordable for all. Using technology, Keia supports healthcare professionals to reach new heights with its best-in-class suite of cloud-based business management software which is designed to make it easy for them to manage and grow their businesses.
JammToday is an online platform designed to assist users in comparing and reviewing various robo- and passive investment providers. By allowing users to input their investment objectives and preferences, JammToday generates a tailored list of suitable digital investment managers. This service addresses the significant advice gap in the UK, where millions lack access to traditional financial advice. The platform simplifies the investment process by providing direct links to the chosen providers' websites, enabling users to complete their investment journey seamlessly. JammToday effectively serves both novice savers and experienced investors, making it easier to navigate the diverse landscape of robo-investing options.
Mynurva aims to make world class behavioural health accessible for everyone within the UK. Our Mission is to transform the service provision of behavioural health using technology to make high quality, reliable services accessible anywhere, discreetly and securely.
Chainvine is a developer of a blockchain-based cloud platform that provides enterprise-grade infrastructure for managing identity, assets, and encryption. Its services encompass a range of applications, including asset management systems, identity management systems, and distributed ledgers. By leveraging blockchain technology, Chainvine enhances accountability, security, and operational efficiency for businesses. The platform features intelligent contracts that allow companies to record essential data, such as time zones and geographic borders, which facilitates better decision-making and improves financial margins. Current live projects include initiatives focused on identity management, intelligent commodities, and sustainable investments, all supported by Chainvine's advanced technology.
Touch Biometrix Ltd is a UK-based company that designs and develops innovative fingerprint authentication sensors for the consumer electronics sector. Established in 2017 and headquartered in Conwy, the company focuses on creating a versatile sensing and algorithm platform that allows for fingerprint sensors of various shapes and sizes. This technology is engineered for seamless integration into mobile devices and other smart objects, enhancing user-friendly identity authentication. By employing advanced sensor designs and algorithms, Touch Biometrix aims to provide a secure and convenient alternative to traditional password systems, enabling a range of products to deliver high-performance fingerprint authentication at competitive cost points.
VTime is a virtual reality software company focused on redefining virtual engagement and communication through innovative applications and cloud-based solutions. Its flagship product, vTime, is a social VR app that allows users to connect and interact in immersive environments. Available for free since December 2015, vTime has attracted hundreds of thousands of users globally, establishing itself as a leader in the European technology sector. The platform facilitates meaningful connections by offering unique ways to engage with friends, family, and communities in virtual settings, enabling users to chat and share media while spending quality time together, regardless of their physical locations.
Liverpool ChiroChem (LCC) is a chemistry-focused contract research organization (CRO) specializing in the production of chiral small molecules for the biotechnology and pharmaceutical sectors. The company offers a range of products, including building blocks, fragments, and screening compounds that facilitate small molecule drug discovery. LCC's advanced chemical technologies enable efficient access to novel chiral building blocks, which are essential for hit identification and hit-to-lead optimization. Their catalytic methods produce a diverse array of chiral amines with high enantiomeric purity. With an initial emphasis on chiral piperidines and sp3-rich nitrogen heterocycles, LCC's offerings are particularly valuable for drug development due to their favorable pharmacokinetic properties, such as improved solubility and bioavailability. The company's innovative technologies have emerged from years of research in asymmetric hydrogenation and Pd-coupling, and LCC actively collaborates with clients to enhance key steps in synthetic processes.
Renephra Ltd. is a medical device company based in Manchester, United Kingdom, established in 2009. It specializes in developing innovative Transdermal Fluid Removal (TFR) technology aimed at addressing fluid overload and chronic conditions such as oedema and lymphoedema. The company's devices utilize a micro-needle system combined with negative pressure therapy to facilitate minimally invasive fluid removal from the skin. This technology targets significant clinical needs within vascular and oncology patients, representing a large and underserved market estimated at £1 billion globally. Having achieved proof of concept in human trials, Renephra is currently seeking funding to advance its device development and feasibility studies.
Zilico is developing the next generation of cancer diagnostics that will provide real-time diagnosis for cervical cancer and reduce the inherent subjectivity of current methods. Two applications are under development: the first for the referral market and the second for the screening market.
Keia is the online destination that connects practitioners and consumers of wellness services, spanning 27 areas and growing, with a mission to make wellness services accessible and affordable for all. Using technology, Keia supports healthcare professionals to reach new heights with its best-in-class suite of cloud-based business management software which is designed to make it easy for them to manage and grow their businesses.
HurricaneLCE is a fully compliant landed cost engine. It draws up on over 100 years combined experience in Logistics, Transport and IT, and brings together true specialists to deliver a flexible solution. We offer a flexible pricing structure that allows you to budget for your tax and import duty calculations.
Cell Lane Ltd
Seed Round in 2017
Cell Lane Ltd has been established to develop a cell isolation and separation platform technology, based on intellectual property assigned from the University of Leeds. This new technology seeks to assist in the future treatment of chronic diseases such as cancer and AIDS, and is intended to enable new fields of research in research activities such stem cell research. The Company’s proposed technology can be used to rapidly separate cells whilst preserving their functionality and overall viability. Cell Lane is in the process of developing its technology to a point where it has a Minimum Viable Product (‘MVP’), the MVP (i.e. the new platform) will then be developed and taken forwards to be commercialised by the Company.
Pacla Medical is the creator of BackHug, an innovative robotic device designed to alleviate back pain and improve spinal flexibility. Utilizing patent-protected technology, BackHug employs 26 robotic fingers to deliver deep tissue pressure to the center of the back and shoulder blades, achieving an average pain reduction of 51%. The accompanying BackHug App personalizes treatment plans through an in-app consultation, allowing users to adjust strength and parameters in real-time. The device also monitors back relaxation levels and utilizes artificial intelligence to optimize treatment based on user data. With a growing customer base, users report significant savings on traditional treatments, averaging over $500 per month, and typically engage with the device 2-3 times a week. Employing approximately 16 staff across the UK and Vietnam, Pacla Medical aims to transform the lives of over 197 million individuals suffering from back pain and related conditions.
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatory conditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need.
Pathfinder Medical is focused on creating a novel electronic guidance system that facilitates minimally invasive connections between blood vessels. This innovative catheter-based technology is designed specifically for treating kidney failure, allowing for vascular access creation that can be performed outside of traditional operating rooms. The system aims to improve the reliability of hemodialysis access for patients, addressing a significant market opportunity valued at £1.6 billion annually. By reducing the likelihood of failure, Pathfinder Medical’s solution enhances treatment options for patients requiring dialysis, showcasing its potential impact in the healthcare sector.
Tookie Limited, founded in 2015 and headquartered in Liverpool, United Kingdom, specializes in developing and selling innovative medical vests specifically designed for children undergoing chemotherapy. The Tookie Vest for Oncology secures central venous catheters (CVCs), which are used for long-term medical treatments, thereby addressing a critical need for enhanced safety and comfort. Traditional methods of securing CVCs often lead to discomfort and anxiety for both patients and their parents, as lines may be left loose or inadequately taped. Tookie's vests aim to alleviate these issues by providing a secure fit that minimizes the risk of inadvertent catheter fallout and reduces the likelihood of infections, ultimately improving the overall well-being and quality of life for young patients.
DynamX Medical specializes in developing an innovative precancer screening system designed for rapid tissue biopsy analysis. This system is user-friendly and can be operated at the point of care by nurses, enhancing accessibility in clinical settings. The company's medical software aims to streamline the disease diagnosis process by increasing the speed and reliability of detection. This technology not only improves diagnostic efficiency but also helps healthcare institutions alleviate the strain on their resources. Through its advancements, DynamX Medical seeks to make significant contributions to early disease detection and patient care.
Pacla Medical is the creator of BackHug, an innovative robotic device designed to alleviate back pain and improve spinal flexibility. Utilizing patent-protected technology, BackHug employs 26 robotic fingers to deliver deep tissue pressure to the center of the back and shoulder blades, achieving an average pain reduction of 51%. The accompanying BackHug App personalizes treatment plans through an in-app consultation, allowing users to adjust strength and parameters in real-time. The device also monitors back relaxation levels and utilizes artificial intelligence to optimize treatment based on user data. With a growing customer base, users report significant savings on traditional treatments, averaging over $500 per month, and typically engage with the device 2-3 times a week. Employing approximately 16 staff across the UK and Vietnam, Pacla Medical aims to transform the lives of over 197 million individuals suffering from back pain and related conditions.
T-EDTA
Venture Round in 2017
T-EDTA Limited was established to develop anti-biofilm technologies and infection control products. Anti-biofilm is used in advanced wound care products using the anti-biofilm agents tri sodium/tetra sodium EDTA (‘t-EDTA’). A biofilm is a group of microorganisms in which cells stick to each other and often adhere to a surface, such as wound. As such, they represent a major risk of woundsite infection. EDTA is a chemical which can inhibit the development of such biofilms. Biofilms are a major problem for human infections and medical device related infections due to their becoming resistant to antibiotics, with the result being wounds that are slow to heal, or not healing/remaining open. The patented tri and tetrasodium EDTA (‘T-EDTA’) can be used to prevent and control infection in three specific areas; advanced wound care, catheters and consumer wellness (Skin/foot fungal infections).
Levitex Foams Ltd specializes in the development and manufacturing of therapeutic mattresses designed to improve body alignment and posture, particularly for individuals who are bed-bound. Recognizing the significant risks associated with poor posture, such as pressure sores and sleep deprivation, the company has created a postural management sleep system, classified as a class 1 medical device. This innovative product is particularly beneficial for patients suffering from complex neurological conditions, including Multiple Sclerosis, Cerebral Palsy, Motor Neurone Disease, and those recovering from stroke or hypoxic brain injury. Levitex Foams aims to enhance patient comfort and health outcomes by providing a range of soft yet supportive pillows, toppers, and mattresses. The company is also a registered supplier to the National Health Service (NHS), reflecting its commitment to quality and efficacy in the healthcare market.
Keia is the online destination that connects practitioners and consumers of wellness services, spanning 27 areas and growing, with a mission to make wellness services accessible and affordable for all. Using technology, Keia supports healthcare professionals to reach new heights with its best-in-class suite of cloud-based business management software which is designed to make it easy for them to manage and grow their businesses.
Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.
SurveyMe is a real-time customer feedback application developed by Afin Technologies, designed to facilitate the collection of immediate feedback from users while offering rewards and coupons as incentives. This innovative platform stands out by efficiently integrating the feedback process with reward mechanisms, making it a unique tool for businesses seeking to enhance customer engagement. SurveyMe allows companies to capture 'Point of Experience' feedback quickly and cost-effectively, transforming this data into actionable management information within seconds. By doing so, it supports risk management and business development efforts, enabling organizations to make informed decisions based on customer insights.
VoxSmart Limited is a telecommunications software provider focused on the financial services sector, offering solutions to manage business risk and comply with regulatory requirements. Founded in 2006 and based in London, the company specializes in its VSMART platform, which captures, records, stores, transcribes, and analyzes mobile communications, including calls, messages, and voicemails, across various devices and networks. By turning communications data into actionable insights, VoxSmart enables firms to enhance their understanding of employee conduct, operational efficiency, and potential business opportunities. The company has formed a strategic alliance with Eventus Systems, Inc., further extending its capabilities in the market.
EligoChem Ltd specializes in the design and development of amphiphilic compound libraries aimed at enhancing drug discovery processes. Founded in 2012 and located in Sandwich, United Kingdom, the company offers a range of services, including the provision of drug-like compounds for screening and support in medicinal and computational chemistry for lead optimization. EligoChem has developed proprietary technology that enables the creation of highly water-soluble drugs, which are better absorbed by the human body. This technology is particularly advantageous for antibiotic drug discovery, as it addresses the challenge of sourcing compounds with desirable solubility characteristics. By focusing on the unique properties of amphiphilic compounds, EligoChem aims to improve the efficacy of drug development and provide safer drugs by design.
RealSpace is a cloud-based software empowering real estate professionals to effectively manage all aspects of running their business online. Real Space Limited has developed a novel, wide field-of-view multi-purpose synoptic virtual reality viewer called ‘SingleReality’, to exploit what the founders perceive as a gap in the growing VR market for a completely new headset design that offers a best-in-class user experience and is also significantly cheaper than other current available market offerings. The Company’s strategy is to offer a superior VR experience by delivering identical images to each eye from a single 2D, high resolution image. This synoptic approach is a novel addition to the VR Head-Mounted Display device market.
Viscgo Limited is a company based in Warrington, United Kingdom, founded in 2015. It specializes in designing, developing, and delivering innovative devices and technology aimed at improving the management of dysphagia, a condition that affects individuals with swallowing disorders. Viscgo's product line includes drink thickness testers that enable accurate measurement of the viscosity of various liquids and textured-modified foods. This technology aids patients, caregivers, and clinicians by ensuring that fluids are properly mixed to provide a smooth consistency, thereby enhancing the safety and quality of care in settings such as hospitals, care homes, schools, and nurseries.
Parkure is a new company with an innovative approach to discovering cure for #Parkinsons disease by drug screening and #repurposing.
Transcriptogen Ltd. is focused on developing novel transcription factor inhibitors for cancer treatment. The company specializes in discovering inhibitors for key transcription factors such as NF-κB, STAT3, HIF1, and AP1, which are critical in regulating gene expression and cancer cell growth. Its lead compound, TSG1301, is a hybrid molecule that selectively binds to DNA, targeting the NF-κB recognition site and demonstrating effectiveness against breast and pancreatic cancer in preclinical models with low toxicity. Transcriptogen also offers a drug discovery platform, the TSG Drug Discovery Engine, to facilitate the identification of additional transcription factor inhibitors for future clinical applications. Furthermore, the company's pharmacogenomics assays are designed to identify patients with dysregulated transcription factor signaling, enabling tailored clinical trial participation and treatment strategies. Established in 2013 and based in Bath, United Kingdom, Transcriptogen aims to leverage the potential of small molecules in the fight against cancer.
PeptiGelDesign provides hydrogels and bioinks to the life science industry.
Filisia addresses the training, rehabilitation and access requirements of people with special education and rehabilitation needs through creative and connected technology. Filisia estimates that there are over 150 million people globally with special education and rehabilitation needs. Cognitive, communication, and physical training is essential, but expensive, repetitive, and often viewed as not always engaging for the person receiving it. Existing technological solutions are often viewed as unattractive and do not provide significant data insights. The result is slower recovery and training, suboptimal therapy results and increased care costs. Filisia’s patent pending software has a number of key features that have been designed with therapists. The software has modules for differing conditions and offers gamified rehabilitation exercises. Multiple difficulty levels tests both physical and cognitive abilities. The software also collects and displays data on clients’ and can record cumulative data to show improvement, flat line or decline in the users outputs.
Funnel Music is a new model in the creation and marketing of new music. Centering around disrupting the development and marketing of acts using our shared outcome agreement, we are able to develop artists for longer and with less debt.
Fen EP Limited is a developer of biomedical devices focused on preventing sudden cardiac death. The company specializes in invasive cardiac electrophysiology instrumentation, which is based on academic research involving paced electrogram fractionation analysis. This technology enables healthcare professionals to predict the risk of sudden cardiac death, allowing for timely interventions and potentially saving lives.
Pronec Ltd seeks to develop a new class of cancer therapy that causes tumours to simply die, using proprietary peptides. The Company has identified a lead candidate molecule that causes necrosis of a wide range of tumour cell lines in culture, but does not affect normal cell lines. Cancer cell necrosis refers to death of cancer cells within a tumour. This new class of compounds is protected by GB and international patent applications.
Elucid mHealth is a medication technology company creating adherence monitoring tools and virtual health platform aimed at improving clinical trial efficiencies. Elucid's novel product, Pill Connect, provides trial organizers with real-time adherence data and missed dose prevention, new dose data, protocol control, engagement measurements and automated dose reconciliation.
Aurio Limited is focused on developing innovative solutions for individuals suffering from tinnitus, a common auditory condition characterized by the perception of sound without an external source. The company has created a unique musical application that utilizes masking technology to deliver tailored sound experiences, targeting the ear most affected by tinnitus. This approach not only helps alleviate the distressing symptoms associated with tinnitus, such as insomnia, anxiety, and poor concentration, but also enhances the quality of daily communication for users. With a significant portion of the adult population affected by this condition, particularly those over 60, Aurio's technology aims to provide relief and improve overall well-being for tinnitus sufferers through engaging and calming soundscapes.
Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, specializing in the development of portable infrared spectroscopy devices for the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Established in 2013, the company has created a hand-held device that utilizes Fourier transform infrared spectroscopy (FTIR) to analyze sputum samples for specific biomarkers associated with COPD. This innovative technology allows patients to perform diagnoses and monitor their health from home, facilitating early detection and management of respiratory diseases. By identifying particular spectral signatures in the samples, the device supports healthcare professionals in assessing and understanding patients' conditions more effectively.
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatory conditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need.
Videregen Limited is a regenerative medicine company based in Liverpool, United Kingdom, focused on developing organ replacement products to combat the chronic shortage of organs for transplantation. Established in 2011 as a spin-out from the Northwick Park Institute of Medical Research, the company specializes in creating biological scaffolds for organ regeneration, particularly targeting trachea, small bowel, and liver replacements. Utilizing decellularized organ scaffolds, Videregen's technology enables the seeding of these scaffolds with a patient’s own stem cells, resulting in personalized, non-immunogenic organ replacements. The company aims to pioneer commercially available organ replacement products, addressing critical health challenges and enhancing patient quality of life while potentially reducing healthcare costs.
AlgaeCytes Limited has developed a proven innovative approach to the production of Omega 3 fatty acids, which are polyunsaturated fatty acids used in numerous bodily functions, such as controlling blood clotting and building cell membranes in the brain. Associated with many health benefits, including protection against heart disease and possibly stroke, new studies are identifying potential benefits for a wide range of conditions including cancer, inflammatory bowel disease and other auto-immune diseases such as lupus and rheumatoid arthritis.
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatory conditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need.
Connect Childcare develops nursery management software designed to enhance the efficiency of childcare facilities. Their integrated systems streamline administrative tasks such as assessments, progress reports, and planning, allowing staff to focus more on child development. By reducing paperwork and simplifying processes, Connect Childcare aims to improve the operational effectiveness of nurseries and ultimately contribute to better outcomes for children.
Arterius Limited is developing a novel next-generation polymer-based Bio-resorbable Coronary Scaffold (BRS), more commonly known as a ‘stent’. The bio-resorbable attribute allows the stent to dissolve over time, typically 12–24 months, before being absorbed by the body. Therefore, there is no requirement to physically remove the stent. The Company’s solution offers a huge opportunity to minimise the frequency of surgery or medical interventions and could give patients a better post-operative quality of life.